Clinical trial · Observational
Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer
a Feasibility Study of Accelerated Hypofractionated Radiotherapy in Node Positive Breast Cancer Patients Treated With Surgery
NCT04792346CI-TRIAL-00050581HIPOMAMMLINFcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Post-operative loco-regional (LR) hypofractionated radiotherapy (Hypo-RT) is an attractive approach in locally advanced breast cancer (LABC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| breast/chest wall radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- acute toxicity assessment
- timeFrame
- 60 months
- description
- rate of acute toxicity according to CTCAE v4.0 scale
Secondary outcomes (1)
- measure
- to evaluate late toxicity
- timeFrame
- 60 months
- description
- rate of late to according to soma lent scale
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients affected by invasive breast cancer who underwent conservative breast surgery or mastectomy and axillary dissection, followed by post operative radiotherapy at the level of the breast/chest wall, and of the supraclavicular, third axillary level +/- internal mammary chain nodes. * pT1-3 disease pN1-2, cT1-3 disease if neoadjuvant chemotherapy , cN + cytologically and/or histologically assessed; * ECOG Performance status ≤2; * histologically negative surgical margins * no distant metastases * no prior chest radiotherapy * life expectancy ≥ 5 years * no prior cancer Exclusion Criteria: * Non-epithelial breast cancer (sarcoma, lymphoma etc.) * Metastases at the level of the internal chain mammary and / or supra-clavicular lymph nodes histologically assessed * pT4 neoplasms or inflammatory breast carcinoma * Distant metastasis * Concomitant chemotherapy * history of prior controlateral breast tumor
References
Publications (0)
Data not yet available
No reference posted for this study.